NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

vTv Therapeutics Inc. (VTVT) Stock Analysis

vTv Therapeutics Inc. (VTVT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

VTVT

$27.77

−$0.07 (−0.27%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare VTVT with… →

VTVT Key Statistics

As of Oct 21, 2026
Trading
Open
$28.06
Previous Close
$27.85
Day's Range
27.55–29.24
52-Week Range
19.50–44.00
Volume
14.14K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.21
Valuation
Market Cap
$109.80M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.98
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.72
Financials (FY)
Revenue (FY)
$0.00−100.00%
Net Income (FY)
−$26.97M
Profit marginThe share of revenue left as profit after all costs and taxes.
−12.91%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
3.95M
1-Year Return
+32.24%
Dividend and dates
Earnings Date
November 13, 2026estimated
Avg Volume
60.38K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, VTVT closed at $27.77, +32.24% over 1 year.

vTv Therapeutics Inc. (VTVT) has a market capitalization of $109.80M.

In fiscal 2025, VTVT reported revenue of $0.00.

VTVT Stock Return by Calendar Year

vTv Therapeutics Inc. (VTVT) 10-year return: what $10,000 became

1 year
$10,000 $13,224
+32.24%
5 years
$10,000 $4,821
−51.79%
10 years
$10,000 $1,019
−89.81%

If you had invested $10,000 in vTv Therapeutics Inc. (VTVT) 10 years ago, at the close on October 21, 2016, it would have been worth $1,019 at the close on October 21, 2026: −89.81% in total, −20.41% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−30.56%
2025+189.59%
2024+20.08%
2023−56.64%
2022−33.37%
2021−46.51%
2020+9.41%
2019−35.85%
2018−55.91%
2017+24.43%
2016 (partial year)−10.56%

As of October 21, 2026.

VTVT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$26.97M—
2024$1.02M−$18.46M−1,815.3%
2023$0.00−$20.25M—
2022$2.02M−$19.16M−949.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$32.81M−$26.97M—
2024$1.02M—−$24.18M−$18.46M−1,815.3%
2023$0.00—−$25.50M−$20.25M—
2022$2.02M—−$22.54M−$19.16M−949.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

VTVT Valuation vs Biotechnology Median

Median of 608 stocks
MetricVTVTBiotechnology medianvs median
P/S ratio2.9813.300.2x the median
Profit margin−12.91%−38.31%25.4 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 13 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

vTv Therapeutics Inc. (VTVT) carries a market capitalisation of $109.80M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 26 employees.

VTVT last closed at $27.77 on October 21, 2026. That is −$0.07 (−0.27%) against the previous close. The 52-week range on file runs from $19.50 to $44.00. The latest close sits 42.41% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. That is −100.00% against the prior fiscal year, when revenue was $1.02M. The same year closed with a net loss of $26.97M. Profit margin runs at −12.91%. That is 25.4 percentage points above the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to −0.72.

Across the 4 fiscal years on file, revenue moves from $2.02M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 2.98. On price-to-sales that is 0.2 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Beta against the wider market is reported at 0.21. Annualized volatility over the trailing 10 years is 120.47%. Over the trailing twelve months the total return is +32.24%. Measured over 10 years, that is −20.41% a year compounded.

Growth & Income

No dividend is on file for VTVT.

The strongest complete calendar year on file is 2025 at +189.59%; the weakest is 2023 at −56.64%. Of the 9 complete calendar years on file, 4 finished higher. 2026 is still running; the total return is −30.56% year to date.

Peer Comparison

vTv Therapeutics Inc. (VTVT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
vTv Therapeutics Inc. VTVT $109.80M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. vTv Therapeutics Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About vTv Therapeutics Inc.

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.

Visit website →